Early Failure Is Like Yeast: Early Triage Boosts Big Pharma's R&D Productivity - Tufts
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
One of the strengths of the big pharma R&D model is the ability to triage candidates early in development, a recent study of R&D productivity at the top 50 pharmaceutical firms by the Tufts Center for the Study of Drug Development suggests.
You may also be interested in...
Has FDA Reached A "New Normal"? Parexel Thinks Lower Review Metrics May Be Here To Stay, Though FDA Hopes To Improve
Shortly after the third anniversary of the FDA Amendments Act, the repercussions of FDA's new authorities and responsibilities for drug review performance are becoming clearer
Parexel Sees Surge In NME Filings, But Also Lower Chance Of Approval
Parexel welcomed signs of a recovery in the submissions of new molecular entities for FDA approval during 2009, floating the possibility that one major reason for the relative drought in truly new drugs entering the market in the last several years - declines in industry R&D productivity - may be easing up
First Cycle Approval Rate Tops 50% For 2006 NMEs; Merck Hits 100%
Merck skillfully navigated FDA’s approval process in 2006, receiving all five of its new molecular entity and novel biologic approvals after only a single review cycle.